Daxor Corporation · NASDAQ:DXR
Daxor — Investor Presentation (November 2023)
44 slides from Daxor's investor presentation, November 2023
Slide 1: Corporate Presentation November 2023
Corporate Presentation November 2023 Nasdaq: DXR
Slide 2: Forward-Looking Statement
Forward-Looking Statement Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channe
Slide 3: COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 4: Daxor is the global leader in blood volume measurement technology
owns and operates a 20,000 SF Daxor is the global leader in blood volume state-of-the-art production and R&D facility in Oak Ridge, TN measurement technology focused on blood volume testing innovation. COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 5: Optimal Blood Volume Management Is Key to Improving Outcomes
Optimal Blood Volume Management Is Key to Improving Outcomes ~130M Patients U.S. Healthcare Burden Heart Failure $30+ Billion Hypertension $48.6+ Billion Critical Care $121-263 Billion COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 6: Managing Volume Derangement is a Challenge for Inpatient & Outpatient Care
Managing Volume Derangement is a Challenge for Both Inpatient & Outpatient Care The Goal: Get the Patient to Their Optimal Blood Volume & Don’t Over Treat Risks of Hypovolemia: Risks of Hypervolemia: • Tissue Hypoperfusion • Heart Failure Decompensation • Acute Kidney Injury • Accelerated Disease •
Slide 7: The Heated Debate at Bedside
“Should we try another treatment strategy?” The Heated Debate at Bedside Her hematocrit is very low. But she’s I think we need to find I think he’s still a bit wet, been getting lots of fluids. It’s not true another treatment he needs to be diuresed. anemia, it’s dilutional. strategy. COPYRIGHT © 20
Slide 8: Optimal Blood Volume is Central to Effective Heart Failure Management
Optimal Blood Volume is Central to Effective Heart Failure Management Other Volume Diagnostics are Inaccurate, Costly, and Invasive – Often Leading to Inferior Outcomes Single BVA-100 Single BVA-100 Bloo Blood Test COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 9: 98% Accurate: Leader in the New Measure of Care
Leader in the New Measure of Care Over 65,000+ Tests Performed Results FDA-Cleared Achievable Within 1 Hour 98% Accurate Inpatient Administered Direct Measurement at Point of + Care of Total Blood Volume, Outpatient Plasma, & Red Cell Volume Over 145+ Peer- Reviewed Studies Confirming Blood Volume S
Slide 10: Who We Are
DAXOR BVA-100 WHO WE ARE
Slide 11: History of Innovation
History of Innovation INCREASING EVIDENCE GROWING TRACTION First RCT demonstrates Completed contracts from mortality benefit in ICU U.S. DoD for simpler, RESEARCH faster, POC portable (Yu 2011) Volume derangement analyzer – U.S. Air Force, shown clinically meaningful Heterogeneity of HF NIH/CAPCaT i
Slide 12: Executive Summary: August 2022 – July 2023, Unaudited
Executive Summary: August 2022 – July 2023, Unaudited COMMERCIAL CLINICAL NEW PRODUCTS • 30.0% increase YOY in diagnostic kit sales • New data from Baptist Heart Health • 510k submission in 2023 for POC device presented at ISHLT validating the rapid bedside test with results in 15 • Implemented an 8
Slide 13: What We Do
DAXOR BVA-100 WHAT WE DO
Slide 14: Mission and Vision
Mission Advance healthcare by enabling optimal fluid management with blood volume analysis. Vision Optimal blood volume for all. COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 15: The New Measure of Care – Moving from the Lab to the Bedside
The New Measure of Care – Moving from the Lab to the Bedside 98% Accurate Measurement Utilizes the Results of Total Blood, “Gold Standard” Achievable Plasma, & Red Methodology Within 1 Hour Cell Volume Available for Optimizes Drives Dramatic Inpatient & Treatments & Clinical Cost Outpatient Outcomes
Slide 16: Over 65,000+ Tests Performed to Evaluate Blood Volume
Over 65,000+ Tests Performed to Evaluate Blood Volume COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 17: Reference Lab for BVA – No Capital Investment or Lab Work
Reference Lab for BVA– No Capital Investment or Lab Work Daxor’s state-of-the-art CLIA certified facility provides on-demand, next day blood volume analysis results. COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 18: Innovation & Next Generation Products
DAXOR BVA-100 INNOVATION & NEXT GENERATION PRODUCTS
Slide 19: Game-Changing, Next-Generation BVA Submission in 2023
Game-Changing, Next-Generation BVA Submission in 2023 Simple, quick, portable blood volume analyzer for POC use and in addition the development of a second novel fluorescent tracer expanding use into more clinical settings for more indications. Recipient of Over $3 Million in Military Contract Award
Slide 20: Clinical Validation
DAXOR BVA-100 CLINICAL VALIDATION
Slide 21: Providing a Solution for the Most Common & Costly Conditions
Providing a Solution for the Most Common & Costly Conditions Blood volume derangements are common in a broad range of medical and surgical conditions including heart failure, critical care, sepsis, syncope, surgical blood loss, and ARDS. Heart Failure Critical Care Sepsis Syncope Surgical Blood Loss
Slide 22: Making a Difference in Multiple Medical Conditions
Making a Difference in Multiple Medical Conditions Patients With Critical Blood Volume Derangements in the U.S. Annually • Heart Failure: 6+M patients, 11M deaths, 1M annual hospitalizations • Critical Care/Sepsis: 8+M admissions annually • Broadening focus indications include combat casualty care,
Slide 23: Study Shows BVA Significantly Improves Heart Failure Treatment
Study Shows BVA Significantly Improves Heart Failure Treatment “The use of Daxor’s BVA-100 blood test in heart failure outcomes in this compelling study showed exceptional value by not only improving patient life span, but also at a cost which is significantly less than other commonly used therapies
Slide 24: BVA On Admission Results in 2.6 Days Reduction in Length of Stay
BVA On Admission Results in 2.6 Days Reduction in Length of Stay Average LOS = 2.0 Days Average LOS = 4.6 Days 57% Reduction in BVA Group Length of Stay Control Group Substantial Savings for Provider Hospitals National Average Days 0 1 2 3 4 5 6 7 6.5 Days Analysis of 71 Hospitalized Heat Failure Pa
Slide 25: BVA Significantly Improves Patient Outcomes in Critical Care
BVA Significantly Improves Multiple Measures of Patient Outcomes in Critical Care “Every clinician understands the importance of maintaining normal blood volume, but the problem is how to measure it. The blood volume analyzer will mitigate the heated debate at the bedside.” Dr. Mihae Yu †M. Yu, K. P
Slide 26: On-Going Trials 2022-2023
“Volume management is key to the successful management of heart failure and we On-Going Trials 2022-2023 are excited to study the utility of BVA in the setting of acute heart failure.” Duke University Medical Center Prospective randomized control First-of-it’s-kind multicenter BVA-100 study in hospi
Slide 27: Recent Published Data 2020-2023
Recent Published Data 2020-2023 COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 28: Business Model
DAXOR BVA-100 Business Model
Slide 29: Sales Model
Sales Model BVA-100 Device Price Volumex Single Use Kit Price Razor/Razorblade Model Acquisition: $85,000 $385 + S&H • Sale & lease of BVA-100 diagnostic systems Lease: $2,750 Per Month • Recurring sales of single BVA Reference Lab Services use test kits • Multi-million-dollar $965 contract awards &
Slide 30: National Hospital Medicare Payment Rate
National Hospital Medicare Payment Rate – Private Payer Rates Even Higher Bundled *National Payment Rate Disclaimer: The signing parties agree that Customer is purchasing laboratory nuclear medicine services and/or products "under arrangement" from Daxor's CLIA-certified laboratory, and Daxor shall
Slide 31: Excellent Value in Healthcare with Reimbursement
Excellent Value in Healthcare with Reimbursement Blood Volume-Guided Treatment Extremely Cost-Effective‡ Retrospective analysis in hospitalized heart failure patients | n = 245, Mixed HFpEF/HFrEF Well above 0.227 previously reported§ Far below the threshold of $50,000 ‡ Strobeck JE, Feldschuh J, Wil
Slide 32: Large, Sustainable, Serviceable Markets at Moderate Penetration Rates
Large, Sustainable, Serviceable Markets at Moderate Penetration Rates Addressable Market – Annual Recurring Revenue $2.3B Heart Failure $2,500 ~6M patients, 30% penetration $2,695 = 1.8M tests $2,000 $3.1B Critical Care, Sepsis $1,463 $1,500 ~8M patients, 20% penetration = 1.6M tests $1,000 $683 $61
Slide 33: Commercialization Channels
Commercialization Channels • Direct sales to major medical centers, hospitals & clinics for both inpatient & outpatient settings • Sales & clinical support team of 12 • International expansion with ISO 13485 certification • Military contract awards • Partnerships with Heart Failure Society of Americ
Slide 34: Patent, Research & Development Activity
Patent, Research & Development Activity 6 3 3 4 4 US Patents Awarded 20,000 SF 6 Research Facility Equipped with New Patents Filed New Patents State-of-the-Art Level 2021-2023 Anticipated for 2023 4 Clean Rooms Patents Pending plus numerous international patents (Europe, Japan, Canada, and the World
Slide 35: COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 36: Daxor is a MedAxiom Industry Partner
Daxor is a MedAxiom Industry Partner Working Together to Achieve the Quadruple Aim Better Outcomes Quadruple Aim Lower Costs Improved Patient Experience Improved Clinical Experience COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 37: BVA Value Impact – the Quadruple Aim and More
BVA Value Impact – the Quadruple Aim and More Prevent Hospital Readmissions Improve Quality Metrics Individualize Treatment to Optimize Outcomes Reduce Length of Stay Inform Fluid Management Early Improve Mortality Save Hospital Resources COPYRIGHT © 2023 DAXOR CORPORATION. ALL RIGHTS RESERVED.
Slide 38: Growth Catalysts & Value Drivers
Growth Catalysts & Value Drivers Increasing distribution through programs with leading clinical & commercial alliances. Next-generation technology a leap in speed & ease of use. Additional clinical outcomes supplementing the clinical & economic benefits. Extensive R&D drives unique & expanding techn
Slide 39: Managing for Growth
Managing for Growth Institutionalizing adoption Expanding distribution Advancing diagnostic & Strong R&D with usage protocols & through direct sales force, therapeutic strategic with next generation device treatment guidance & 3rd party distributors alliances launch in 2023 Expanding studies Growing
Slide 40: Key Metrics
Key Metrics 1940 Act Reporting Company | Publicly Traded Since 1971 Stock Symbol: DXR Exchange: Nasdaq Recent Price: $7.53 (a/o 11/17/23) 52 Week Range: $7.26 to $13.13 Market Cap: $36.2M (a/o 09/08/23) Shares Outstanding: 4.8M Free Float: 2.0M Insider Ownership: 57.4% Net Assets: $28.5 (a/o 11/17/2
Slide 41: Highlights
Highlights Game changing next generation system set for submission in 2023 Diagnostic kit revenue growth 30.0% YOY Broad and deep IP portfolio with patented technology Over 140+ peer-reviewed published studies Clean capital structure, strong balance sheet, no warrants, small float Provides individua
Slide 42: Senior Leadership
Senior Leadership Michael Feldschuh Jonathan Feldschuh Robert Michel, CPA, MBA President and Chief Scientific Officer Chief Financial Officer Chief Executive Officer Harvard University Villanova University Columbia University St John’s University, MBA Kathryn A. Kornafel, Jean Oertel Linda Cooper MT
Slide 43: Key Contacts
Key Contacts Investor Relations Transfer Agent Bret Shapiro Continental Stock Transfer CORE IR 1 State Street, 30 Floor, NY, NY 10004 377 Oak Street, Garden City, NY 11530 212-509-4000 | cstmail@continentalstock.com 516-222-2560 | brets@coreir.com www.continentalstock.com www.coreir.com Corporate Co
Slide 44: Daxor.com contact details
107 Meco Lane, Oak Ridge, TN 37830 865-425-0555 | info@daxor.com Daxor.com